Glitazone scrips up 34%

The number of scrips for glitazones increased by 33.5 per cent between 2005 and 2006 in England, according to a DoH Information Centre report.

The report on diabetes prescribing in England revealed that 2.1 million prescriptions for glitazones, at a cost of £94 million, were written in 2006.

Rosiglitazone remained the most commonly prescribed glitazone, with over 1.4 million prescriptions.

The use of rosiglitazone in combination with metformin increased to exceed rates of pioglitazone prescriptions.

Findings that link rosiglitazone to a 63 per cent increased risk of death from cardiovascular cause, are expected to affect future prescribing patterns.

Last month the European Medicines Agency said prescribing information for rosiglitazone must include a warning that in patients with ischaemic heart disease rosiglitazone should only be used after careful evaluation of risk.

Prescribing for diabetes in England

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from shielded patient list, deputy CMO suggests

Most children could be removed from the shielded patient list in a future wave of...

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide some care for shielded patients in clinical settings, NHS England confirms

GPs can provide care to shielded patients in 'infection-controlled clinical settings'...

How digital assistants can help patients manage their health and wellbeing

How digital assistants can help patients manage their health and wellbeing

A project in Staffordshire has shown how practices can make use of digital technology...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

Fair death-in-service deal for locums vital before second COVID-19 wave, warns BMA

The government must do ‘the right thing’ and secure adequate death-in-service benefits...

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP workload fears over antibody testing rollout for 'no clinical benefit'

GP practices are being contacted by patients asking for antibody tests as the government...